Biogen (BIIB) shares down 3% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

Biogen (NASDAQ: BIIB) is recently down 3% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 30, December is at 48; compared to its 52-week range of 28 to 45.

You May Also Be Interested In

• Levi (LEVI) call put ratio 1 call to 1.2 puts into quarter results
• Biogen (BIIB) PT Raised to $157 at HSBC
• Ares Management (ARES) call put ratio 7.8 calls to 1 put with a focus on 1600 contracts of August 150 calls